Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

Shirish Gadgeel, Alice T. Shaw, Fabrice Barlesi, Lucio Crino, James Chih-Hsin Yang, Anne-Marie C. Dingemans, Dong-Wan Kim, Filippo de Marinis, Mathias Schulz, Shiyao Liu, Ravindra Gupta, Ahmed Kotb, Sai-Hong Ignatius Ou

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalBritish Journal of Cancer
Volume118
Issue number1
DOIs
Publication statusPublished - 9 Jan 2018

Keywords

  • alectinib
  • ALK positive
  • central nervous system
  • cumulative incidence rates
  • disease progression
  • non-small-cell lung cancer
  • phase II
  • CELL LUNG-CANCER
  • OPEN-LABEL
  • CRIZOTINIB

Cite this

Gadgeel, S., Shaw, A. T., Barlesi, F., Crino, L., Yang, J. C-H., Dingemans, A-M. C., Kim, D-W., de Marinis, F., Schulz, M., Liu, S., Gupta, R., Kotb, A., & Ou, S-H. I. (2018). Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. British Journal of Cancer, 118(1), 38-42. https://doi.org/10.1038/bjc.2017.395